Simbec-Orion Group
10
1
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
30.0%
3 terminated/withdrawn out of 10 trials
57.1%
-29.4% vs industry average
10%
1 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
Role: collaborator
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Role: collaborator
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
Role: collaborator
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
Role: collaborator
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
Role: collaborator
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
Role: collaborator
Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers
Role: collaborator
Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients
Role: collaborator
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
Role: collaborator
Single Ascending Oral Dose Study of F901318
Role: collaborator
All 10 trials loaded